| Drug General Information |
| Drug ID |
D0I3RD
|
| Former ID |
DNCL002184
|
| Drug Name |
TAK-733
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1]
|
|---|
| Company |
Millennium Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H15F2IN4O4
|
| Canonical SMILES |
CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(C=N2)CC(C<br />O)O
|
| InChI |
1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1
|
| InChIKey |
RCLQNICOARASSR-SECBINFHSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
56261361, 57491481, 109817139, 123085249, 124360782, 125088028, 125164695, 136340206, 136349518, 136367649, 136920418, 137276031, 141825911, 162011961, 162038037, 163563819, 163620753, 163686073, 163763291, 185990504, 189622834, 223389322, 223704301, 224388375, 227729806, 245337742, 252451636
|
| Target and Pathway |
| Target(s) |
MEK protein kinase |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Oocyte meiosis
|
|
PI3K-Akt signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Dorso-ventral axis formation
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Gap junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Toll-like receptor signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Melanogenesis
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Prion diseases
|
|
Alcoholism
|
|
Hepatitis B
|
|
Influenza A
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Thyroid cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Insulin Signalling
|
|
Reactome
|
MAPK3 (ERK1) activation
|
|
Uptake and function of anthrax toxins
|
|
RAF activation
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
TCR Signaling Pathway
|
|
ErbB Signaling Pathway
|
|
Hypothetical Network for Drug Addiction
|
|
Senescence and Autophagy in Cancer
|
|
EPO Receptor Signaling
|
|
Regulation of Actin Cytoskeleton
|
|
IL-2 Signaling Pathway
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Bladder Cancer
|
|
Cardiac Hypertrophic Response
|
|
MAP kinase activation in TLR cascade
|
|
RAF/MAP kinase cascade
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nifedipine Activity
|
|
PDGF Pathway
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Corticotropin-releasing hormone
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
B Cell Receptor Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
Endothelin Pathways
|
|
IL-7 Signaling Pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
IL-1 signaling pathway
|
|
Signaling by FGFR
|
|
Integrin-mediated Cell Adhesion
|
|
L1CAM interactions
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Regulation of toll-like receptor signaling pathway
|
|
Osteopontin Signaling
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00948467) Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health. |
|---|
| REF 2 | MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. |
|---|
